Compare with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES JUBILANT LIFE SCIENCES ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x - 15.2 - View Chart
P/BV x 6.6 1.8 375.5% View Chart
Dividend Yield % 0.7 0.8 77.5%  

Financials

 ALKEM LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
JUBILANT LIFE SCIENCES
Mar-19
ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,589898 176.9%   
Low Rs1,232618 199.5%   
Sales per share (Unadj.) Rs417.5572.0 73.0%  
Earnings per share (Unadj.) Rs56.336.2 155.4%  
Cash flow per share (Unadj.) Rs64.759.5 108.7%  
Dividends per share (Unadj.) Rs12.704.50 282.2%  
Dividend yield (eoy) %0.90.6 151.6%  
Book value per share (Unadj.) Rs292.9301.9 97.0%  
Shares outstanding (eoy) m119.57159.28 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 255.1%   
Avg P/E ratio x25.120.9 119.8%  
P/CF ratio (eoy) x21.812.7 171.2%  
Price / Book Value ratio x4.82.5 191.8%  
Dividend payout %22.612.4 181.6%   
Avg Mkt Cap Rs m168,653120,694 139.7%   
No. of employees `000NA2.4 0.0%   
Total wages/salary Rs m9,17119,260 47.6%   
Avg. sales/employee Rs ThNM38,120.6-  
Avg. wages/employee Rs ThNM8,058.4-  
Avg. net profit/employee Rs ThNM2,414.3-  
INCOME DATA
Net Sales Rs m49,91591,108 54.8%  
Other income Rs m1,645357 460.3%   
Total revenues Rs m51,56191,466 56.4%   
Gross profit Rs m8,48217,390 48.8%  
Depreciation Rs m1,0063,709 27.1%   
Interest Rs m6712,198 30.5%   
Profit before tax Rs m8,45111,840 71.4%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,6063,268 49.1%   
Profit after tax Rs m6,7315,770 116.7%  
Gross profit margin %17.019.1 89.0%  
Effective tax rate %19.027.6 68.9%   
Net profit margin %13.56.3 212.9%  
BALANCE SHEET DATA
Current assets Rs m27,06245,848 59.0%   
Current liabilities Rs m15,32420,897 73.3%   
Net working cap to sales %23.527.4 85.9%  
Current ratio x1.82.2 80.5%  
Inventory Days Days6757 117.1%  
Debtors Days Days4151 81.0%  
Net fixed assets Rs m12,61065,498 19.3%   
Share capital Rs m239159 150.1%   
"Free" reserves Rs m34,49047,930 72.0%   
Net worth Rs m35,02748,089 72.8%   
Long term debt Rs m1,21242,429 2.9%   
Total assets Rs m54,387114,685 47.4%  
Interest coverage x13.66.4 213.0%   
Debt to equity ratio x00.9 3.9%  
Sales to assets ratio x0.90.8 115.5%   
Return on assets %13.66.9 195.9%  
Return on equity %19.212.0 160.2%  
Return on capital %24.912.4 200.2%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56312,422 52.8%   
Fx outflow Rs m3,01217,227 17.5%   
Net fx Rs m3,552-4,805 -73.9%   
CASH FLOW
From Operations Rs m7,25911,215 64.7%  
From Investments Rs m1,864-10,118 -18.4%  
From Financial Activity Rs m-9,2736,574 -141.0%  
Net Cashflow Rs m-1507,612 -2.0%  

Share Holding

Indian Promoters % 66.9 45.6 146.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 33.1 8.7 380.5%  
FIIs % 0.0 21.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.1 -  
Shareholders   68,381 23,815 287.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - CADILA HEALTHCARE COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS